Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.

Completed · Phase 4

Conditions studied: Atopic Dermatitis

In brief

The purpose of this study is to assess a bilateral comparison between pimecrolimus cream 1% (Elidel®) and a medical device cream (EletoneTM) in the treatment and management of atopic dermatitis. Study subjects will apply pimecrolimus twice daily for four weeks on a target area located on one side of the body, and apply the medical device cream three times daily for four weeks on the opposite side of the body at a target lesion symmetric to the other.

Key facts

Study ID

NCT01177566

Run by

Emer, Jason, M.D.

People needed

20

Starts

2009-09-01

Expected to finish

2010-03-01

Last updated by the study team

2010-08-09

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Males and females ≥ 2 years old.
• Subjects must be in good general health as confirmed by medical history and physical examination.
• Females of child-bearing potential must have a negative urine pregnancy test at the baseline visit and agree to use adequate birth control during the study (barrier, oral, injection, intrauterine). NOTE: Post-menopausal (amenorrheic for at least one year) and surgically sterile (tubal ligation and/or hysterectomy) are considered to be of non child-bearing potential.
• Clear diagnosis of atopic dermatitis for at least one year.
• Subject must have a static Physician's Global Assessment (PGA) of at least 2 (mild severity) for each selected target lesion
• Disease must be stable or slowly worsening for more than one week prior to entering the study.
• Subjects must be able to read, sign, and date the informed consent, and abide by study restrictions for its duration.

You may not qualify if…

• Females who are pregnant, attempting to conceive, or breastfeeding.
• Subjects with known hypersensitivity to study drug.
• Subjects with overt signs of skin atrophy, telangiectasias and/or striae in the target area.
• Subjects with a current active skin malignancy or infection.
• Subjects requiring the use of medications known to alter the course of atopic dermatitis during the study treatment.
• Subjects who have received systemic antibiotics within 2 weeks.
• Subjects using systemic corticosteroids or immunosuppressants within 28 days of entering the study.
• Subjects who have received topical corticosteroids or other topical therapies (tar, calcineurin inhibitors) for atopic dermatitis within 7 days of entering the study.
• Subjects using phototherapy (UVB, PUVA) within 28 days of entering the study.
• Subjects who are currently participating in or, with in the previous 28 days, have participated in another study for the treatment of atopic dermatitis.
• Subjects with clinical conditions that may post a health risk to the subject by being involved in the study or detrimentally affect regular follow-up of the subject.

Where it is running

• Mount Sinai School of Medicine Department of Dermatology Clinical Trials — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.